HC Wainwright Issues Pessimistic Outlook for ELVN Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Enliven Therapeutics in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.60) per share for the quarter, down from their prior forecast of ($0.53). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Enliven Therapeutics' Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.45) EPS and FY2026 earnings at ($2.81) EPS.

Separately, Jones Trading cut their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $37.25.

Enliven Therapeutics Stock Down 5.4%

Shares of ELVN opened at $16.86 on Monday. The business has a 50-day simple moving average of $18.84 and a two-hundred day simple moving average of $21.65. The stock has a market cap of $827.30 million, a price-to-earnings ratio of -8.87 and a beta of 1.07. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06).

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $265,330. This represents a 20.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Anish Patel sold 6,667 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total value of $122,606.13. Following the transaction, the chief operating officer now directly owns 309,976 shares of the company's stock, valued at approximately $5,700,458.64. The trade was a 2.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Polar Capital Holdings Plc boosted its stake in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after buying an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC bought a new position in Enliven Therapeutics during the fourth quarter valued at approximately $15,106,000. Janus Henderson Group PLC boosted its stake in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock valued at $30,001,000 after buying an additional 290,153 shares during the last quarter. FMR LLC boosted its stake in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock valued at $146,157,000 after buying an additional 199,692 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock valued at $21,877,000 after buying an additional 135,969 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.